Table 3. A comparison of the neutralizing antibody levels between the two groups.
| D0 | D7 | D14 | D45 | D180 | D360 | |
|---|---|---|---|---|---|---|
| Group A | ||||||
| Number of subjects | 79 | 79 | 73 | 73 | 65 | 66 |
| GMT, IU/ml | ||||||
| Value (95% CI) |
0.29 (0.26–0.34) |
1.12 (0.96–1.30) |
21.90 (19.06–25.17) |
8.28 (6.51–10.41) |
4.13 (3.20–5.33) |
3.72 (2.69–5.15) |
| Range, IU/ml |
0.19–0.39 | 0.09–4.9 | 6.76–134.90 | 1.32–165.96 | 0.83–58.88 | 0.37–97.72 |
| n ≥ 0.5 IU/ml (%) |
0/79 (0) | 70/79 (88.6%) | 73/73 (100%) | 73/73 (100%) | 65/65 (100%) | 62/66 (93.9%) |
| Group B | ||||||
| Number of subjects | 102 | 102 | 102 | 100 | 58 | 20 |
| GMT, IU/ml | ||||||
| Value (95% CI) |
0.16 (0.10–0.28) |
1.39 (1.17–1.67) |
19.93 (16.99–23.37) |
7.89 (6.73–9.26) |
4.02 (3.12–5.19) |
2.58 (1.546–4.31) |
| Range, IU/ml |
0.07–0.44 | 0.11–46.77 | 1.91–169.82 | 1.55–165.96 | 0.79–37.15 | 0.52–15.49 |
| n ≥ 0.5 IU/ml |
0/102 (0) | 89/102 (87.3%) | 102/102 (100%) | 100/100 (100%) | 58/58 (100%) | 20/20 (100%) |